Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
SMARCA2/4 degraders relieve the differentiation block in AML via changes in chromatin looping and accessibility
Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
Discovery of potent and paralog selective PROTAC degraders of CBP or p300 proteins for the treatment of various cancers
Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers
Identification of SMARCA2/4 degraders for the treatment of SMARCA4-mutant and other cancers (SMARCA2/4 degraders)
In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4
In silico designing of targeted protein degraders
Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Targeting SWI/SNF ATPases in enhancer-addicted human cancers
Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia
Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor SITC, Nov 2022
